Sihuan Pharma Stock Price, News & Analysis
SHPHY
OTC
Company Description
Sihuan Pharmaceutical Holdings Group Ltd, a global medical aesthetic and biopharmaceutical company, focuses on areas like medical aesthetics, oncology, diabetes, and more. Its innovative subsidiary, Xuanzhu Biopharmaceutical, recently obtained NMPA approval for Anaprozole Sodium Enteric-coated Tablet, a groundbreaking first-in-China proton pump inhibitor. This milestone marks the transition from R&D to commercialization, providing safe and effective treatment options for duodenal ulcer and potentially reflux esophagitis. With a strategic focus on innovation and global growth, Sihuan Pharmaceutical aims to become a leading company in the medical aesthetics and biopharmaceutical industry.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$0.0
Market Cap
231.1M
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Sihuan Pharma.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What areas does Sihuan Pharmaceutical focus on?
Sihuan Pharmaceutical focuses on high-growth therapeutic areas such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular, cerebrovascular, modern Chinese medicine, and industrial hemp.
What recent achievement did Xuanzhu Biopharmaceutical reach?
Xuanzhu Biopharmaceutical obtained NMPA approval for Anaprozole Sodium Enteric-coated Tablet, the first proton pump inhibitor fully independently developed in China.
What are the main characteristics of Anaprozole Sodium Enteric-coated Tablet?
Anaprozole tablets effectively inhibit the secretion of gastric acid, have fast onset, stable therapeutic effect, low risk of drug interactions, and excretion through the gut and kidney for safer use in patients with renal insufficiency.
What is the strategic objective of Sihuan Pharmaceutical?
Sihuan Pharmaceutical's strategic objective is to promote a two-wheeled strategy of medical aesthetics and biopharmaceuticals to become a leading company in China.
What is the focus of Xuanzhu Biopharmaceutical?
Xuanzhu Biopharmaceutical focuses on major diseases like digestion, oncology, and non-alcoholic steatohepatitis, developing class 1 drugs with core proprietary intellectual property rights.
What are the R&D platforms of Xuanzhu Biopharmaceutical?
Xuanzhu Biopharmaceutical has two R&D platforms: small molecule chemistry and large molecule biologics, driving innovation and forming a broad product pipeline.
How does Sihuan Pharmaceutical drive innovation?
Sihuan Pharmaceutical is committed to continuous research and development, production, and commercialization of innovative drugs to address unmet clinical medical needs, focusing on international competitiveness.
What is the company's vision for the future?
The company aims to develop into a first-class innovative pharmaceutical company with independent research and development, production, and sales capabilities, serving human health with innovative drugs.
What is the market potential of Anaprozole Sodium Enteric-coated Tablet?
Anaprozole Sodium Enteric-coated Tablet has huge commercial potential and clinical value in the market due to its excellent clinical performance and acceptance by doctors and patients.
How can I learn more about Sihuan Pharmaceutical?
Visit the company website at https://www.sihuanpharm.com/ or contact ir@sihuanpharm.com for further information.